HeartBeam Unveils AI Program Designed to Deliver Unprecedented Personalized Cardiac Insights

Company Appoints Mohammad Shokoohi-Yekta to Lead Program and Industry Pioneer Lance Myers as Advisor

SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced significant developments for the use of artificial intelligence (AI) applied to its proprietary vectorelectrocardiography (VECG) technology, including the addition of new leadership and advisory roles. By coupling machine learning methods with the company’s VECG technology, HeartBeam aims to provide physicians with unprecedented diagnostic and prognostic insights about cardiac health that it believes will exceed the information provided by a standard 12-lead electrocardiogram (ECG).

HeartBeam’s core VECG technology collects 3D signals of the heart and converts them into an easy-to-interpret 12-lead ECG. Designed to be used with portable, patient-friendly devices, the company’s first planned application of the platform technology is its HeartBeam AIMIGo™, the first and only credit card-sized device that provides a 12-lead ECG to facilitate remote evaluation of cardiac symptoms.

The HeartBeam technology gathers more data than a standard 12-lead ECG by capturing signals in 3 projections (X,Y,Z) that, when taken together, generate a complete 3D map of the heart’s electrical activity. By leveraging AI to analyze these data-rich signals, HeartBeam believes it will be able to improve diagnostic accuracy and extract unique information that today’s 12-lead ECGs are unable to detect, such as complex heart rhythms, subtle signs of deteriorating heart health and cardiac events that may have previously been missed. In addition, as the device is used by the same patient over time, there will be a series of readings for each patient – data that is of great diagnostic value. HeartBeam believes this presents a unique opportunity to create a comprehensive repository of data that could unlock personalized AI-driven insights to improve cardiac care.

“It’s rare to acquire a large series of 12-lead ECGs from the same individual over time,” said Branislav Vajdic, PhD, CEO and Founder of HeartBeam. “By pioneering a user-friendly device that enables frequent 12-lead ECGs over time and by coupling AI with our proprietary VECG technology that can go beyond a 12-lead ECG, HeartBeam is well-positioned to identify nuanced cardiac trends that could ultimately improve patient care.”

To lead this effort, the company has hired Mohammad Shokoohi-Yekta, PhD, as Senior Director of Machine Learning. A renowned expert in the field of data science and machine learning, Dr. Shokoohi-Yekta was most recently at Microsoft. During his tenure at Microsoft, he spearheaded the use of advanced analytics, machine learning techniques and predictive modeling to improve the accuracy of software tools. He also played a pivotal role in growing a small team of data scientists and AI professionals into one of the most influential teams within the organization, resulting in a significant financial impact. He previously held data science and machine learning positions at Apple and has been a keynote speaker at more than 60 data and AI summits around the world. Dr. Shokoohi-Yekta received his PhD in Computer Science from the University of California, Riverside.

Additionally, Lance Myers, PhD, a pioneer in digital health data analytics and body-worn biosensor technologies, will be joining HeartBeam as Chief AI Advisor. Previously, Dr. Myers was the Head of Cardiovascular Devices and Head of Data Science at Verily Life Sciences, where he led a team developing a novel heart failure monitoring solution and built strong leadership in computational biology, biosensor algorithms, digital biomarkers, health informatics and digital pathology. He also held leadership roles at Sentrian, VivoSense, Boston Neurosciences and Vivometrics. He currently serves as a board member for VivoSense and is on the scientific advisory boards of Acorai and Bryte. Dr. Myers received his PhD in Biomedical Engineering from the University of Cape Town in South Africa.

“Having Mohammad and Lance join the company will be invaluable as we work towards our mission of transforming cardiac health. With their expertise and acumen, I am confident both will make an immediate impact to harness the power of AI within our data-rich VECG technology to ensure we deliver the most impactful technology with the goal of improving patient outcomes,” added Dr. Vajdic.

About HeartBeam, Inc.

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company that is dedicated to transforming cardiac care through the power of personalized insights. The company’s proprietary vectorelectrocardiography (VECG) technology collects 3D signals of the heart’s electrical activity and converts them into a 12-lead ECG. This platform technology is designed to be used on portable, patient-friendly devices such as a credit-card sized monitor, watch or patch. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining how cardiac health is managed in the future. For additional information, visit HeartBeam.com.

Forward-Looking Statements

All statements in this release that are not based on historical fact are “forward-looking statements.” While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Contacts

Investor Relations Contact:
Chris Tyson

Executive Vice President

MZ North America

Direct: 949-491-8235

BEAT@mzgroup.us
www.mzgroup.us

Media Contact:
media@heartbeam.com